Effects of a beta blocker and spironolactone on plasma homocysteine levels.
Korkmaz
Mehmet E
ME
Atar
Ilyas
I
Tayfun
Egemen
E
Yildirir
Aylin
A
Ulucam
Melek
M
Ozin
Bülent
B
Muderrisoglu
Haldun
H
Turan
Munire
M
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006710:Homocysteine / Q000097:blood* / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D012720:Severity of Illness Index; D013148:Spironolactone / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D015415:Biomarkers; D004232:Diuretics; D006710:Homocysteine; D013148:Spironolactone; D008790:Metoprolol